Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Active, not recruiting · NCT06523621 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-07-13 | NCT06523621 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Atrium Health Levine Cancer Institute | 27 |
| Bristol-Myers Squibb | 422 |
| Wake Forest University Health Sciences | 284 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Levine Cancer Institute | Charlotte | United States | 110 |